• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta ‐analysis
ConclusionsUse of NOACs compared to VKAs significantly reduced the risk of bleeding in patients with AF ablation. Similarly, the risk of bleeding was lower with uninterrupted NOACs than with uninterrupted VKAs, and with interrupted NOACs than with interrupted VKAs. The rate of thromboembolic complications was extremely low in both study groups without any differences.
Source: Cardiovascular Therapeutics - September 12, 2018 Category: Cardiology Authors: Zhen Ge, Michela Faggioni, Usman Baber, Samantha Sartori, Sabato Sorrentino, Serdar Farhan, Jaya Chandrasekhar, Birgit Vogel, Abdul Qadeer, Jonathan Halperin, Vivek Reddy, Srinivas Dukkipati, George Dangas, Roxana Mehran Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research

Non Vitamin K Oral Anticoagulants versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments yield Novel Insights
ConclusionsFor the primary‐outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced haemorrhagic‐stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential haemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary‐outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung‐Fat Tse, Ian J Lauder Tags: Unsolicited Review Source Type: research